Next clinical study plans supported by patient perspectives group

In 2018 Biosignatures plans to initiate a multisite study to evaluate the utility and efficiency of the Videometrics system with the cystograph (bladder mapping) technology. As part of the initial planning for this study, we attended a Perspectives In Cancer Research Group meeting. This is a group of volunteers who all have personal experience of cancer, the group objective is to support cancer research at the Freeman Hospital in Newcastle.

The meeting gave us a valuable insight into the patient perspective of the system and the utility of the bladder mapping technology as a tool to assist in the patient pathway and current procedures.

Biosignatures are looking for hospitals to be involved in the study, if you would like to be involved, or have any questions, please contact Sarah Groves our Clinical Operations Manager:

Email: Sarah.groves@biosignatures.co.uk
Phone: +44 (0) 191 645 3645

Technical development has already started on the creation of a map of the bladder walls, however, no video has yet provided us with full coverage of the bladder. We hope this study can demonstrate the utility of a systematic review of the whole bladder.

Videometrics Released to Regulatory

Development of version 1 of Videometrics is now complete and the system has been released for regulatory review.

October was a busy month of bug fixing, document production and updates for the Videometrics development team. The system is now going through regulatory approval and is expected to be fully released with a CE mark in early 2018.

The Videometrics system, a combination of a high-quality video recorder and video review software, will be available from 2018. A key potential benefit of using Videometrics in the cystoscopy clinic is the ability to train and support nurses and junior doctors to run the cystoscopy clinics with remote support of Consultant Urologists. Any areas of concern can be recorded as a video clip and shared along with notes to the Consultant for review, the aim being to prevent unnecessary follow-up procedures for the patients.

The system is currently being demonstrated nationwide. Interested? To find out more or book an onsite demonstration of the software and discussion of the benefits for your clinic contact us:

info@bladderimaging.com
0191 645 3645

The Videometrics software / hardware combination will be available in early 2018.
The Videometrics system will be available from early 2018.

 

Exciting and busy months ahead for the Videometrics team

July looks set to be a busy month for the Videometrics team.

We’d like to thank everyone who took the time to visit our stand at BAUS, especially those who referred their hardware suppliers to us. Many congratulations to Professor Rob Pickard for winning the St Peter’s Medal.

After a successful trip to BAUS, there are just a few final touches to add to the system and completion of regulatory procedures before the official launch of the system later this year.

The CICERO study is ongoing and we hope to have some preliminary results to present in the near future.

Whilst all this work is being finalised, we will be travelling the UK with the system for demonstrations and further discussions.

Get in touch with Will Dracup (will.dracup@bladderimaging.com) to arrange a demonstration.

Videometrics conference demonstration set up
Our stand at BAUS 2017.

Biosignatures and TotalLab team up to take Videometrics to market

Videometrics was originally developed by Biosignatures Ltd, when one of the company’s key staff went through the bladder cancer patient care pathway and was able to see the challenges for himself. Talking with care givers, he was quickly able to see how his and the company’s background in developing advanced computer image analysis systems could help in bladder cancer diagnosis.

Now that the product is getting ready for launch, TotalLab Ltd, a related party company of Biosignatures, with a long track record of looking after customers all over the world, is going to take over the commercialisation of the product so that Biosignatures can focus on developing it’s diagnostic blood tests.